GURUFOCUS.COM » STOCK LIST » USA » NAS » Neuronetics Inc (NAS:STIM) » Definitions » Cash-to-Debt
Switch to:

Neuronetics Cash-to-Debt

: 1.84 (As of Jun. 2022)
View and export this data going back to 2018. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Neuronetics's cash to debt ratio for the quarter that ended in Jun. 2022 was 1.84.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Neuronetics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Neuronetics's Cash-to-Debt or its related term are showing as below:

STIM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49   Med: 2.16   Max: 3.54
Current: 1.84

During the past 6 years, Neuronetics's highest Cash to Debt Ratio was 3.54. The lowest was 0.49. And the median was 2.16.

STIM's Cash-to-Debt is ranked worse than
53.31% of 242 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.28 vs STIM: 1.84

Neuronetics Cash-to-Debt Historical Data

The historical data trend for Neuronetics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash-to-Debt
Premium Member Only 0.99 3.44 2.23 1.33 2.44

Neuronetics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 2.64 2.44 2.10 1.84

Competitive Comparison

For the Diagnostics & Research subindustry, Neuronetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Neuronetics Cash-to-Debt Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Neuronetics's Cash-to-Debt falls into.



Neuronetics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Neuronetics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Neuronetics's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics  (NAS:STIM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Neuronetics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Neuronetics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics Business Description

Neuronetics logo
Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE ALTA WY 83414
Rosengarten Megan director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Cascella Robert director C/O HOLOGIC, INC. BEDFORD MA 01730
Shook Bruce Joseph director 162 CRICKET AVE ARDMORE PA 19003
Jaeger Wilfred E director C/O THREE ARCH PARTNERS 3200 ALPINE RD PORTOLA VALLEY CA 94028
Bakewell John K director C/O LANTHEUS MEDICAL IMAGING, INC. 331 TREBLE COVE ROAD NO. BILLERICA MA 01862
Conley Sheryl L director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Muir Glenn P director C/O HOLOGIC, INC. BEDFORD MA 01730
Sullivan Keith J director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC. 464 ELLIS STREET MOUNTAIN VIEW CA 94043
Macan William Andrew officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600 KATY TX 77494
Harper Gregory officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Furlong Stephen officer: CFO C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Tropsha Yelena officer: VP of Commercial Access C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Farley Brian E director 2200 ZANKER ROAD SUITE F SAN JOSE CA 95131
Guthrie Daniel officer: Chief Commercial Officer C/O NEURONETICS, INC 322 PHOENIXVILLE PIKE MALVERN PA 19355

Neuronetics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)